Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
HTM I hear you but don't worry I have been in and out numerous times trading this company. I only saying that HTM possibly will drift lower now that it broke a significant support or go side ways until next e's or positive news.
HTM I hear you but don't worry I have been in and out numerous times trading this company. I only saying that HTM possibly will drift lower now that it broke a significant support or go side ways until next e's or positive news.
HTM broke support, not good
CBLI With good volume too
CBLI back up after profit taking y'day
CBLI +60,32% higher than in PM. Big news no one is on it
Ohhh dear...Whats with these multiple posts everytime I post???
MSTX on the move
Possibly next event : Additional clinical data expected Q3 2014 from 29 pulmonary arterial hypertension (PAH) patients
LOOOOL
Whut???? You're posting too fast. Wait a few seconds and try posting again. And maybe consider switching to decaf...
MSTX on the move
Possibly next event : Additional clinical data expected Q3 2014 from 29 pulmonary arterial hypertension (PAH) patients
LOOOOL
Whut???? You're posting too fast. Wait a few seconds and try posting again. And maybe consider switching to decaf...
MSTX on the move
Possibly next event : Additional clinical data expected Q3 2014 from 29 pulmonary arterial hypertension (PAH) patients
MSTX on the move
Possibly next event : Additional clinical data expected Q3 2014 from 29 pulmonary arterial hypertension (PAH) patients
CBLI granted Fast Track status to entolimod and Orphan Drug status for prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster.
HTM sad but true. I expect the stock to drift lower until next e's or a surprise event occurs.
I am little worried about their cash and I'm hoping they can strike a deal (Enbridge or another partner?) sooner rather than later.
HTM California lawmakers abandoned proposed legislation -- ending their session Saturday without a vote -- that would have ordered the state's major investor-owned utilities to buy more electricity from power plants that harness underground heat from deep within the earth's crust.
Gm, the body cam has been a point of discussion here also in Europe.
MSTX september 9 Rodman And Renshaw 16th Annual Global Investment Conference
MSTX september 9 Rodman And Renshaw 16th Annual Global Investment Conference
MSTX september 9 Rodman And Renshaw 16th Annual Global Investment Conference
HTM ~ tis, no need to apologise, I did understand and appreciated the article you posted.
Correct me if I am wrong but didn't someone wanted them to do business in Canada for funding but they refused?
HTM lots can change in a decade. Geothermal energy accounts for just 0.4 percent of all U.S. electricity output. There is room to grow.
HTM nice add
HTM will this move the stock next week? Their newly acquired geysers are located in Cali but it's not operational yet.
California lawmakers may decide this week whether San Diego County utility customers must underwrite a new fleet of geothermal power plants.
The proposed legislation requires the state’s major investor-owned utilities, including San Diego Gas & Electric, to collectively contract 500 megawatts of electrical generating capacity from new geothermal power plants anywhere within California over the next decade, enough electricity to supply some 300,000 homes.
DEJ Thought so too, straitneom. Love the way they keep investors informed. I am sure one day this will result in higher pps.
DEJ: Co announces that 2014 development operations are underway at the Kokopelli Project.
The new drill pad 21B has been completed including gas connection (please refer to our website for media) and drill pad 21A has been augmented to accommodate the drilling, equipping and utility of a water disposal well that will prove a significant economy to existing water disposal arrangements.
A Peter Martin 'conductor' rig is engaged to complete the 'rat holes' with 20" casing for eight new production wells and one water disposal well prior to the Frontier-28 rig moving in for sequential total depth drilling operations in mid-September.
The 2014 drill program is focused on developing significant new production from the liquids-rich Williams Fork formation (based at 8400') and testing for production from the Mancos reservoir, in particular, the commerciality of deep Niobrara strata (estimated to base at 12,750').
DEJ news coiling
Oy veyyyyy lol
HTM few twitter guys with massive followers pushing for a close 0,70+ and morning gap. Expect a sell off then (unfortunately) :(
HTM I agree Matt, they need that water for cooling
MSTX beautiful chart
http://finviz.com/quote.ashx?t=Mstx&ty=c&ta=1&p=d
Oh dear what's up with the double/triple posts all the time????
MDXH MDxHealth Reports First Half Year 2014 Results
Strong market adoption leads to more than doubling of ConfirmMDx case volume
IRVINE, CA, and HERSTAL, BELGIUM - August 21, 2014 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced results of the first-half year ended June 30, 2014.
"During the first half of 2014, adoption of ConfirmMDx® for Prostate Cancer continued to grow rapidly, with 5,500 patient cases tested, compared to approximately 2,400 cases in the first half of 2013. ConfirmMDx revenue increased sharply to $3.9 million in H1 2014, rising from $0.9 million in the first half 2013. The fast growth of revenue was due to a combination of factors including test volume growth and increased recognition of revenue based on broader non-Medicare insurance coverage and improving payment and collection trends," reported Dr. Jan Groen, CEO of MDxHealth. "We also achieved a significant milestone in the Medicare coverage process during this reporting period. The Local Coverage Determination (LCD) for ConfirmMDx has been posted for public comment, signaling that the test has passed the technical assessment. Following the notification period, we anticipate that the LCD should be effective before the end of 2014."
Business Highlights
ConfirmMDx for Prostate Cancer
?Revenue increased 317% to $3.9 million in H1 2014 over $0.9 million in H1 2013
?Case volume increased 129%, with 5,500 patients tested in H1 2014 compared to 2,400 patients tested in H1 2013
?Published clinical utility study in the journal American Health and Drug Benefits
?DOCUMENT validation study published in the Journal of Urology
?Presented data regarding the prognostic value of the ConfirmMDx test genes at the 2014 ASCO Genitourinary (GU) Seminar
?Signed co-marketing agreements with Long Island Pathology and American Pathology Partners
?Signed an exclusive agreement with Teva Pharmaceutical Ltd. for distribution of ConfirmMDx for Prostate Cancer in Israel
?Signed insurance agreements with additional PPO providers Prime Health Services and Galaxy Health Network, adding nearly 10 million covered lives
?The Centers for Medicare and Medicaid Services (CMS) posted the draft Local Coverage Determination (LCD) for the ConfirmMDx for Prostate Cancer test on its website
Other Business Activities
?MDxHealth and HistoGeneX N.V. were awarded $1.8 million from the Flemish Institute for the Promotion of Innovation by Science and Technology to fund the development of companion diagnostics for cancer immunotherapy
?MDxHealth licensee Exact Sciences published the positive results of its 10,000 patient DeeP-C pivotal clinical study for its Cologuard test in the New England Journal of Medicine
?Data confirming the clinical utility of PredictMDx® for Glioblastoma test published in the New England Journal of Medicine
?MDxHealth received approval from the Belgium tax authority for patent income deductions (PID), which allows for an 80% deduction of qualifying gross patent income. PID treatment is granted to Belgian companies who support investments in technical innovation which stimulate ownership of patents and promotes business based on these patents. PID reduces the effective tax rate from 34% to 6.8% for the qualifying income.
Events After the Reporting Period
?Validation Study demonstrating the prognostic value of ConfirmMDx biomarker published in The Journal of Urology®
?CMS initiated National Coverage Analysis for screening for colorectal cancer using Exact Sciences Cologuard test, and posted the related Proposed Decision Memorandum on its website.
?MDxHealth licensee Exact Sciences received FDA approval for its Cologuard colon cancer screening assay
?Signed two insurance agreements with Ancillary Care Services (ACS), and separately, with Consilium, LLC.
?Signed a co-marketing agreement with Miraca Life Sciences, the largest independent anatomic pathology lab in the U.S., to promote ConfirmMDx.
Financials
Key Figures for the first half (thousands of U.S. dollars, except number of shares and per share data):
As of June 30, 2014 First half year 2014 First half year 2013
Total revenues 4,804 3,984
Total operating expenses 10,434 10,022
EBITDA (Loss) -7,932 -7,525
Operating profit (EBIT) -8,086 -7,820
Net loss -8,043 -7,843
Earnings per share, basic ($) -0.23 -0.23
Number of outstanding shares 34,251,303 34,251,303
Cash and cash equivalents 12,709 32,253
Revenues
Total revenues grew 21% to $4.8 million in H1 2014, compared to $4.0 million in H1 2013. Revenue from ConfirmMDx sales increased 317%, with $3.9 million in H1 2014 compared to $0.9 million in H1 2013. ConfirmMDx represents 81% of the overall revenue mix in H1 2014, as compared to 23% in the same period last year. In H1 2013 50% of MDxHealth's revenue was related to the Merck Cilengitide companion diagnostic project. The Merck agreement was terminated after Merck's Phase III clinical study did not meet its primary endpoints.
Operating Expenses
Operating expenses for H1 2014 were $10.4 million, increasing 4% compared to $10.0 million in H1 2013. This increase was attributable to the continued build-up of the U.S. commercial operations in support of ConfirmMDx for Prostate Cancer test.
Results
As expected, H1 2014 loss increased slightly over the same period in 2013 due to costs associated with growing commercial infrastructure to support U.S. sales and marketing and new product R&D investment. The company's operating loss (EBIT) increased by 3.4%, and the net loss increased by 2.6% in H1 2014.
Cash Position
MDxHealth ended the first half of 2014 with cash and cash equivalents of $12.7 million compared to $32.3 million on June 30, 2013.
Q3 and FY2014 Outlook
In Q3 2014, MDxHealth will begin enrollment in its 600 patient, prospective clinical utility study, PASCUAL, which will generate additional clinical utility data supporting Medicare coverage of the ConfirmMDx for Prostate Cancer test. MDxHealth anticipates that the final LCD for Medicare coverage of ConfirmMDx with data development will be effective in Q4 2014. An interim analysis of the PASCUAL study, as outlined in the Medicare LCD, is expected in the first half of 2015, potentially triggering expanded coverage.
A steady increase in reimbursement from third-party payors was achieved during the period, with more than 155 insurers now paying for the test. With increasing ConfirmMDx test volumes and collections, MDxHealth is able to recognize more accrual-based revenue. However, with growing adoption of the test by new prescribing urologists across the U.S., the company expects a growing number of new payors, thus also increasing the group of non-contracted, third party payors. This could lead to continued delays in collections and revenue recognition among those payors. Any projections provided herein should be considered forward looking statements and are subject to the risks summarized in the safe harbor statement at the end of this press release.
MDxHealth licensee Exact Sciences recently reported on the successful completion of their FDA preapproval inspection (PAI). CMS initiated National Coverage Analysis for screening for colorectal cancer using Cologuard, and posted the related Proposed Decision Memorandum on the CMS website. Exact Sciences reported that it is preparing for commercialization of its Cologuard test, most recently completing the training of an eighty-person direct sales force. In August, Cologuard received FDA approval and the product launch is expected before the end of 2014. MDxHealth is entitled to receive milestone payments and royalties from the sale of the test under the terms of its licensing agreement.
MDXH MDxHealth Reports First Half Year 2014 Results
Strong market adoption leads to more than doubling of ConfirmMDx case volume
IRVINE, CA, and HERSTAL, BELGIUM - August 21, 2014 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced results of the first-half year ended June 30, 2014.
"During the first half of 2014, adoption of ConfirmMDx® for Prostate Cancer continued to grow rapidly, with 5,500 patient cases tested, compared to approximately 2,400 cases in the first half of 2013. ConfirmMDx revenue increased sharply to $3.9 million in H1 2014, rising from $0.9 million in the first half 2013. The fast growth of revenue was due to a combination of factors including test volume growth and increased recognition of revenue based on broader non-Medicare insurance coverage and improving payment and collection trends," reported Dr. Jan Groen, CEO of MDxHealth. "We also achieved a significant milestone in the Medicare coverage process during this reporting period. The Local Coverage Determination (LCD) for ConfirmMDx has been posted for public comment, signaling that the test has passed the technical assessment. Following the notification period, we anticipate that the LCD should be effective before the end of 2014."
Business Highlights
ConfirmMDx for Prostate Cancer
?Revenue increased 317% to $3.9 million in H1 2014 over $0.9 million in H1 2013
?Case volume increased 129%, with 5,500 patients tested in H1 2014 compared to 2,400 patients tested in H1 2013
?Published clinical utility study in the journal American Health and Drug Benefits
?DOCUMENT validation study published in the Journal of Urology
?Presented data regarding the prognostic value of the ConfirmMDx test genes at the 2014 ASCO Genitourinary (GU) Seminar
?Signed co-marketing agreements with Long Island Pathology and American Pathology Partners
?Signed an exclusive agreement with Teva Pharmaceutical Ltd. for distribution of ConfirmMDx for Prostate Cancer in Israel
?Signed insurance agreements with additional PPO providers Prime Health Services and Galaxy Health Network, adding nearly 10 million covered lives
?The Centers for Medicare and Medicaid Services (CMS) posted the draft Local Coverage Determination (LCD) for the ConfirmMDx for Prostate Cancer test on its website
Other Business Activities
?MDxHealth and HistoGeneX N.V. were awarded $1.8 million from the Flemish Institute for the Promotion of Innovation by Science and Technology to fund the development of companion diagnostics for cancer immunotherapy
?MDxHealth licensee Exact Sciences published the positive results of its 10,000 patient DeeP-C pivotal clinical study for its Cologuard test in the New England Journal of Medicine
?Data confirming the clinical utility of PredictMDx® for Glioblastoma test published in the New England Journal of Medicine
?MDxHealth received approval from the Belgium tax authority for patent income deductions (PID), which allows for an 80% deduction of qualifying gross patent income. PID treatment is granted to Belgian companies who support investments in technical innovation which stimulate ownership of patents and promotes business based on these patents. PID reduces the effective tax rate from 34% to 6.8% for the qualifying income.
Events After the Reporting Period
?Validation Study demonstrating the prognostic value of ConfirmMDx biomarker published in The Journal of Urology®
?CMS initiated National Coverage Analysis for screening for colorectal cancer using Exact Sciences Cologuard test, and posted the related Proposed Decision Memorandum on its website.
?MDxHealth licensee Exact Sciences received FDA approval for its Cologuard colon cancer screening assay
?Signed two insurance agreements with Ancillary Care Services (ACS), and separately, with Consilium, LLC.
?Signed a co-marketing agreement with Miraca Life Sciences, the largest independent anatomic pathology lab in the U.S., to promote ConfirmMDx.
Financials
Key Figures for the first half (thousands of U.S. dollars, except number of shares and per share data):
As of June 30, 2014 First half year 2014 First half year 2013
Total revenues 4,804 3,984
Total operating expenses 10,434 10,022
EBITDA (Loss) -7,932 -7,525
Operating profit (EBIT) -8,086 -7,820
Net loss -8,043 -7,843
Earnings per share, basic ($) -0.23 -0.23
Number of outstanding shares 34,251,303 34,251,303
Cash and cash equivalents 12,709 32,253
Revenues
Total revenues grew 21% to $4.8 million in H1 2014, compared to $4.0 million in H1 2013. Revenue from ConfirmMDx sales increased 317%, with $3.9 million in H1 2014 compared to $0.9 million in H1 2013. ConfirmMDx represents 81% of the overall revenue mix in H1 2014, as compared to 23% in the same period last year. In H1 2013 50% of MDxHealth's revenue was related to the Merck Cilengitide companion diagnostic project. The Merck agreement was terminated after Merck's Phase III clinical study did not meet its primary endpoints.
Operating Expenses
Operating expenses for H1 2014 were $10.4 million, increasing 4% compared to $10.0 million in H1 2013. This increase was attributable to the continued build-up of the U.S. commercial operations in support of ConfirmMDx for Prostate Cancer test.
Results
As expected, H1 2014 loss increased slightly over the same period in 2013 due to costs associated with growing commercial infrastructure to support U.S. sales and marketing and new product R&D investment. The company's operating loss (EBIT) increased by 3.4%, and the net loss increased by 2.6% in H1 2014.
Cash Position
MDxHealth ended the first half of 2014 with cash and cash equivalents of $12.7 million compared to $32.3 million on June 30, 2013.
Q3 and FY2014 Outlook
In Q3 2014, MDxHealth will begin enrollment in its 600 patient, prospective clinical utility study, PASCUAL, which will generate additional clinical utility data supporting Medicare coverage of the ConfirmMDx for Prostate Cancer test. MDxHealth anticipates that the final LCD for Medicare coverage of ConfirmMDx with data development will be effective in Q4 2014. An interim analysis of the PASCUAL study, as outlined in the Medicare LCD, is expected in the first half of 2015, potentially triggering expanded coverage.
A steady increase in reimbursement from third-party payors was achieved during the period, with more than 155 insurers now paying for the test. With increasing ConfirmMDx test volumes and collections, MDxHealth is able to recognize more accrual-based revenue. However, with growing adoption of the test by new prescribing urologists across the U.S., the company expects a growing number of new payors, thus also increasing the group of non-contracted, third party payors. This could lead to continued delays in collections and revenue recognition among those payors. Any projections provided herein should be considered forward looking statements and are subject to the risks summarized in the safe harbor statement at the end of this press release.
MDxHealth licensee Exact Sciences recently reported on the successful completion of their FDA preapproval inspection (PAI). CMS initiated National Coverage Analysis for screening for colorectal cancer using Cologuard, and posted the related Proposed Decision Memorandum on the CMS website. Exact Sciences reported that it is preparing for commercialization of its Cologuard test, most recently completing the training of an eighty-person direct sales force. In August, Cologuard received FDA approval and the product launch is expected before the end of 2014. MDxHealth is entitled to receive milestone payments and royalties from the sale of the test under the terms of its licensing agreement.
MDXH MDxHealth Reports First Half Year 2014 Results
Strong market adoption leads to more than doubling of ConfirmMDx case volume
IRVINE, CA, and HERSTAL, BELGIUM - August 21, 2014 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced results of the first-half year ended June 30, 2014.
"During the first half of 2014, adoption of ConfirmMDx® for Prostate Cancer continued to grow rapidly, with 5,500 patient cases tested, compared to approximately 2,400 cases in the first half of 2013. ConfirmMDx revenue increased sharply to $3.9 million in H1 2014, rising from $0.9 million in the first half 2013. The fast growth of revenue was due to a combination of factors including test volume growth and increased recognition of revenue based on broader non-Medicare insurance coverage and improving payment and collection trends," reported Dr. Jan Groen, CEO of MDxHealth. "We also achieved a significant milestone in the Medicare coverage process during this reporting period. The Local Coverage Determination (LCD) for ConfirmMDx has been posted for public comment, signaling that the test has passed the technical assessment. Following the notification period, we anticipate that the LCD should be effective before the end of 2014."
Business Highlights
ConfirmMDx for Prostate Cancer
?Revenue increased 317% to $3.9 million in H1 2014 over $0.9 million in H1 2013
?Case volume increased 129%, with 5,500 patients tested in H1 2014 compared to 2,400 patients tested in H1 2013
?Published clinical utility study in the journal American Health and Drug Benefits
?DOCUMENT validation study published in the Journal of Urology
?Presented data regarding the prognostic value of the ConfirmMDx test genes at the 2014 ASCO Genitourinary (GU) Seminar
?Signed co-marketing agreements with Long Island Pathology and American Pathology Partners
?Signed an exclusive agreement with Teva Pharmaceutical Ltd. for distribution of ConfirmMDx for Prostate Cancer in Israel
?Signed insurance agreements with additional PPO providers Prime Health Services and Galaxy Health Network, adding nearly 10 million covered lives
?The Centers for Medicare and Medicaid Services (CMS) posted the draft Local Coverage Determination (LCD) for the ConfirmMDx for Prostate Cancer test on its website
Other Business Activities
?MDxHealth and HistoGeneX N.V. were awarded $1.8 million from the Flemish Institute for the Promotion of Innovation by Science and Technology to fund the development of companion diagnostics for cancer immunotherapy
?MDxHealth licensee Exact Sciences published the positive results of its 10,000 patient DeeP-C pivotal clinical study for its Cologuard test in the New England Journal of Medicine
?Data confirming the clinical utility of PredictMDx® for Glioblastoma test published in the New England Journal of Medicine
?MDxHealth received approval from the Belgium tax authority for patent income deductions (PID), which allows for an 80% deduction of qualifying gross patent income. PID treatment is granted to Belgian companies who support investments in technical innovation which stimulate ownership of patents and promotes business based on these patents. PID reduces the effective tax rate from 34% to 6.8% for the qualifying income.
Events After the Reporting Period
?Validation Study demonstrating the prognostic value of ConfirmMDx biomarker published in The Journal of Urology®
?CMS initiated National Coverage Analysis for screening for colorectal cancer using Exact Sciences Cologuard test, and posted the related Proposed Decision Memorandum on its website.
?MDxHealth licensee Exact Sciences received FDA approval for its Cologuard colon cancer screening assay
?Signed two insurance agreements with Ancillary Care Services (ACS), and separately, with Consilium, LLC.
?Signed a co-marketing agreement with Miraca Life Sciences, the largest independent anatomic pathology lab in the U.S., to promote ConfirmMDx.
Financials
Key Figures for the first half (thousands of U.S. dollars, except number of shares and per share data):
As of June 30, 2014 First half year 2014 First half year 2013
Total revenues 4,804 3,984
Total operating expenses 10,434 10,022
EBITDA (Loss) -7,932 -7,525
Operating profit (EBIT) -8,086 -7,820
Net loss -8,043 -7,843
Earnings per share, basic ($) -0.23 -0.23
Number of outstanding shares 34,251,303 34,251,303
Cash and cash equivalents 12,709 32,253
Revenues
Total revenues grew 21% to $4.8 million in H1 2014, compared to $4.0 million in H1 2013. Revenue from ConfirmMDx sales increased 317%, with $3.9 million in H1 2014 compared to $0.9 million in H1 2013. ConfirmMDx represents 81% of the overall revenue mix in H1 2014, as compared to 23% in the same period last year. In H1 2013 50% of MDxHealth's revenue was related to the Merck Cilengitide companion diagnostic project. The Merck agreement was terminated after Merck's Phase III clinical study did not meet its primary endpoints.
Operating Expenses
Operating expenses for H1 2014 were $10.4 million, increasing 4% compared to $10.0 million in H1 2013. This increase was attributable to the continued build-up of the U.S. commercial operations in support of ConfirmMDx for Prostate Cancer test.
Results
As expected, H1 2014 loss increased slightly over the same period in 2013 due to costs associated with growing commercial infrastructure to support U.S. sales and marketing and new product R&D investment. The company's operating loss (EBIT) increased by 3.4%, and the net loss increased by 2.6% in H1 2014.
Cash Position
MDxHealth ended the first half of 2014 with cash and cash equivalents of $12.7 million compared to $32.3 million on June 30, 2013.
Q3 and FY2014 Outlook
In Q3 2014, MDxHealth will begin enrollment in its 600 patient, prospective clinical utility study, PASCUAL, which will generate additional clinical utility data supporting Medicare coverage of the ConfirmMDx for Prostate Cancer test. MDxHealth anticipates that the final LCD for Medicare coverage of ConfirmMDx with data development will be effective in Q4 2014. An interim analysis of the PASCUAL study, as outlined in the Medicare LCD, is expected in the first half of 2015, potentially triggering expanded coverage.
A steady increase in reimbursement from third-party payors was achieved during the period, with more than 155 insurers now paying for the test. With increasing ConfirmMDx test volumes and collections, MDxHealth is able to recognize more accrual-based revenue. However, with growing adoption of the test by new prescribing urologists across the U.S., the company expects a growing number of new payors, thus also increasing the group of non-contracted, third party payors. This could lead to continued delays in collections and revenue recognition among those payors. Any projections provided herein should be considered forward looking statements and are subject to the risks summarized in the safe harbor statement at the end of this press release.
MDxHealth licensee Exact Sciences recently reported on the successful completion of their FDA preapproval inspection (PAI). CMS initiated National Coverage Analysis for screening for colorectal cancer using Cologuard, and posted the related Proposed Decision Memorandum on the CMS website. Exact Sciences reported that it is preparing for commercialization of its Cologuard test, most recently completing the training of an eighty-person direct sales force. In August, Cologuard received FDA approval and the product launch is expected before the end of 2014. MDxHealth is entitled to receive milestone payments and royalties from the sale of the test under the terms of its licensing agreement.
MSTX nice volume so far.
MSTX it's about time she makes another move. Been too long in this channel, don't you think.
Wondering if there is news or update on the horizon...
MSTX 0.63 is here, can take you by surprise
DEJ moving back up after last weeks panic sell
MDXH MDxHealth ConfirmMDx Biomarker Associated with the Risk of Recurrence for Early Stage Prostate Cancer Patients
Validation Study Data Published in The Journal of Urology(R)
MdxHealth (TM)
3 hours ago
GlobeNewswire
IRVINE, Calif. and HERSTAL, Belgium, Aug. 18, 2014 (GLOBE NEWSWIRE) -- MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that one of the ConfirmMDx(R) for Prostate Cancer epigenetic genes is independently associated with risk of recurrence in patients with early prostate cancer (PCa). The results from this study, published in The Journal of Urology(R) [The Journal of Urology (2014), doi: 10.1016/j.juro.2014.04.082], suggest that epigenetic analysis could play a clinical role in identifying patients who have a slow growing cancer eligible for active surveillance from those with a higher risk of recurrence who may benefit from a more aggressive therapeutic approach.
One of the most significant challenges in diagnosing early stage PCa is proper staging and grading of the patients in order to choose the best treatment plan. Current methods such as clinical staging, PSA serum level and biopsy tissue Gleason score are helpful, but have limited prognostic value. Therefore, more accurate and objective prediction of PCa disease recurrence is very important. . The gene glutathione S-transferase Pi 1 (GSTP1) is one of the three genes in the ConfirmMDx test and previous studies have indicated that this gene has been associated with different stages of PCa.
"The results of this independent validation study confirm previous data presented at the 2014 ASCO GU Cancer Symposium demonstrating the prognostic value of our ConfirmMDx genes," stated Prof. Dr. Wim van Criekinge, Chief Scientific Officer of MDxHealth. "Furthermore, they illustrate the clinical importance of using epigenetic biomarkers, like GSTP1, to not only identify patients with prostate cancer but also inform the treating urologist about the aggressiveness of the disease for treatment decision making."
The study, conducted by researchers from Johns Hopkins University Medical Center, evaluated the prognostic value of nine epigenetic genes using tissue from 452 patients (259 cases, 193 controls) presenting with biochemical recurrence, clinical recurrence, systemic metastases, or who died of their prostate cancer in a nested case-control study of patients surgically treated for clinically localized PCa. Out of the nine genes, the data showed that higher GSTP1 methylation was the only one significantly associated with an increased risk of recurrence, especially for men with early stage PCa.
MDXH MDxHealth ConfirmMDx Biomarker Associated with the Risk of Recurrence for Early Stage Prostate Cancer Patients
Validation Study Data Published in The Journal of Urology(R)
MdxHealth (TM)
3 hours ago
GlobeNewswire
IRVINE, Calif. and HERSTAL, Belgium, Aug. 18, 2014 (GLOBE NEWSWIRE) -- MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that one of the ConfirmMDx(R) for Prostate Cancer epigenetic genes is independently associated with risk of recurrence in patients with early prostate cancer (PCa). The results from this study, published in The Journal of Urology(R) [The Journal of Urology (2014), doi: 10.1016/j.juro.2014.04.082], suggest that epigenetic analysis could play a clinical role in identifying patients who have a slow growing cancer eligible for active surveillance from those with a higher risk of recurrence who may benefit from a more aggressive therapeutic approach.
One of the most significant challenges in diagnosing early stage PCa is proper staging and grading of the patients in order to choose the best treatment plan. Current methods such as clinical staging, PSA serum level and biopsy tissue Gleason score are helpful, but have limited prognostic value. Therefore, more accurate and objective prediction of PCa disease recurrence is very important. . The gene glutathione S-transferase Pi 1 (GSTP1) is one of the three genes in the ConfirmMDx test and previous studies have indicated that this gene has been associated with different stages of PCa.
"The results of this independent validation study confirm previous data presented at the 2014 ASCO GU Cancer Symposium demonstrating the prognostic value of our ConfirmMDx genes," stated Prof. Dr. Wim van Criekinge, Chief Scientific Officer of MDxHealth. "Furthermore, they illustrate the clinical importance of using epigenetic biomarkers, like GSTP1, to not only identify patients with prostate cancer but also inform the treating urologist about the aggressiveness of the disease for treatment decision making."
The study, conducted by researchers from Johns Hopkins University Medical Center, evaluated the prognostic value of nine epigenetic genes using tissue from 452 patients (259 cases, 193 controls) presenting with biochemical recurrence, clinical recurrence, systemic metastases, or who died of their prostate cancer in a nested case-control study of patients surgically treated for clinically localized PCa. Out of the nine genes, the data showed that higher GSTP1 methylation was the only one significantly associated with an increased risk of recurrence, especially for men with early stage PCa.
DEJ I agree 100% but I feel we will see more news in the near future which could help the pps go back up.
I just read a tread on the same board about a possible JV with Coachman Energy Operating.
Perhaps it's nothing but it does make sense.
This is an excerpt from a pr not so long ago.
The Company also announces the departure of Steven Mut, as Director and Co-Chairman, and Richard Bachmann as Director. Mr. Mut will continue to work closely with Dejour in his role as President of Oil and Gas Operations for Coachman Energy, the General Partner of the Kokopelli field investor Bakken Drilling Fund III (BDF). It was mutually agreed that Steve’s emerging role with BDF could pose the potential for conflict with the fiduciary position he held with Dejour.
And this is from the Coach Energy site:
-Today, Coachman Energy is actively acquiring and aggregating working interests in our target fairway in Williams and Divide Counties, North Dakota––the heart of the Williston Basin. We have also diversified into Colorado’s liquids-rich, gas prone Piceance Basin.-